)

Vivos Therapeutics (VVOS) investor relations material
Vivos Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Completed the acquisition of The Sleep Center of Nevada (SCN) in June 2025, marking a strategic pivot to a direct patient and sleep center provider-based model and away from legacy VIP enrollment revenue.
SCN generated $500,000 in diagnostic revenue in the last 20 days of Q2 2025, with strong patient demand exceeding current capacity.
Initial integration of SCN has exceeded expectations, with strong buy-in from medical staff and higher-than-forecast patient demand for alternatives to CPAP.
Management is actively pursuing additional acquisitions and management agreements, including a new agreement with MISleep Solutions in Michigan, to expand the alliance model.
The business model shift away from VIP dentist enrollments led to a decline in legacy service revenue.
Financial highlights
Q2 2025 revenue was $3.8M, down 6% year-over-year, with six-month revenue at $6.8M, and gross margin declined to 55% from 65% in Q2 2024.
Operating loss widened to $4.9M in Q2 2025 and $8.8M for the first half, reflecting higher expenses and lower revenues during the transition.
Net loss for Q2 2025 was $5.0M, with net loss per share of $0.55; accumulated deficit reached $113.1M as of June 30, 2025.
Cash and cash equivalents stood at $4.4M as of June 30, 2025, with total liabilities of $21.5M and stockholders' equity of $4.6M.
Secured $11.5M in net cash from debt and equity financing, including $8.2M in senior secured notes and $3.7M in private placement.
Outlook and guidance
Management expects revenue growth and higher-margin, more sustainable revenue as SO teams and new alliances are deployed, but acknowledges the new model is unproven and subject to risks.
Targets cash flow positivity by Q4 2025, contingent on rapid SO team deployment and facility expansion.
Additional growth initiatives include expanding diagnostic and treatment services, launching a pediatric OSA program, and collaborating with specialty medical groups.
There is substantial doubt about the ability to continue as a going concern without additional financing.
Next Vivos Therapeutics earnings date

Next Vivos Therapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage